Article Text

PDF
Clinical pharmacy and clinical trials (including case series)
Small cell lung cancer: patients report
  1. M.P. Molina-Guillén,
  2. J. Pastor Cano,
  3. J. León Villar,
  4. M.C. Sánchez Mulero,
  5. B. Arribas Díaz,
  6. A. Boso Ribelles,
  7. A. Morego Soler,
  8. M.I. Sánchez-Quiles,
  9. J.F. Abellan
  1. 1Hospital Morales Meseguer, Hospital Pharmacy, Murcia, Spain
  2. 2Hospital Morales Meseguer, Surgery, Murcia, Spain

Abstract

Background Platinum based chemotherapy is the backbone of small-cell lung cancer (SCLC) therapy. However, how it works in our population has not been evaluated.

Purpose The aim of this study is to evaluate the progression-free interval (PFI) on SCLC patients receiving first line platinum based chemotherapy.

Materials and methods Retrospective observational study focused on patients diagnosed during two years (2009-2010). Data were collected from medical records (treatment orders, Oncofarm® program and medical history). These data were: age, sex, history of smoking, stage of the disease, treatments received, and PFI.

Results Forty patients were diagnosed with SCLC, 4(10%) were women and 36(90%) were men. Average age was 65,3 years (±9,9; 44-84). All the patients have history of smoking, but 30(75%) were active smokers. Fifteen (37.5%) were diagnosed at the limited stage disease (LD) and 25(62.5%) at extended stage disease (ED). Average first line platinum chemotherapy cycles received were 3(1-6), and only one patient did not receive any chemotherapic treatment. First line treatment results on LD patients:

*73,3%(11) patients had a PFI longer than six months. 54,5%(6) of them remain stable at the end of the study, 36,4%(4) received second line chemotherapy and one received palliative treatment.

*20,0%(3) patients had a PFI shorter than six months and received second line chemotherapy.

First line treatment results on ED patients:

*28,0%(7) patients had a PFI longer than six months. 57,0%(4) remain stable at the end of the study, one received second line chemotherapy and 28,6%(2) received palliative treatment.

*68,0%(17) patients had a PFI shorter than 6 months, 47,1%(8) received second line chemotherapy and 52,9%(9) received palliative treatment.

*One patient refused chemotherapy.

Conclusions Platinum based chemotherapy has been shown to be more effective in SCLC patients when they start the treatment at the LD stage. The 73.3% of the patients diagnosed and treated at the LD stage had a PFI longer than 6 months. However, only 28% of the patients who started the treatment at the ED stage reached a PFI longer than 6 months.

Statistics from Altmetric.com

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.